Vyne Therapeutics Stock Performance
| VYNE Stock | USD 1.72 0.04 2.38% |
The entity has a beta of 0.68, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vyne Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vyne Therapeutics is expected to be smaller as well. At this point, Vyne Therapeutics has a negative expected return of -0.53%. Please make sure to validate Vyne Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Vyne Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vyne Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:18 | Last Split Date 2023-02-13 |
1 | Disposition of 24536 shares by David Domzalski of Vyne Therapeutics at 3.35 subject to Rule 16b-3 | 12/31/2024 |
2 | Acquisition by Lepore Patrick G of 15000 shares of Vyne Therapeutics at 2.92 subject to Rule 16b-3 | 01/15/2025 |
3 | Insider Buying Patrick Lepore Acquires 15,000 Shares of VYNE Therapeutics Inc | 01/17/2025 |
4 | Acquisition by David Domzalski of 730000 shares of Vyne Therapeutics at 2.77 subject to Rule 16b-3 | 01/21/2025 |
5 | Vyne therapeutics director Patrick Lepore buys 43,800 in stock - MSN | 01/28/2025 |
6 | Acquisition by Sandoval Elisabeth of 20000 shares of Vyne Therapeutics at 2.7 subject to Rule 16b-3 | 01/31/2025 |
7 | VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis | 02/19/2025 |
8 | Acquisition by Harsch Mutya of 62500 shares of Vyne Therapeutics at 2.7 subject to Rule 16b-3 | 02/21/2025 |
9 | VYNE Therapeutics Promising Pipeline and Strategic Focus Drive Buy Rating - TipRanks | 02/24/2025 |
10 | Disposition of 1719 shares by Iain Stuart of Vyne Therapeutics at 0.223 subject to Rule 16b-3 | 03/04/2025 |
11 | VYNE Therapeutics Releases Quarterly Earnings Results, Misses Expectations By 0.03 EPS | 03/06/2025 |
12 | VYNE Therapeutics Releases Quarterly Earnings Results, Beats Estimates By 0.03 EPS | 03/07/2025 |
13 | Disposition of 1087 shares by Tyler Zeronda of Vyne Therapeutics at 3.83 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 30.7 M |
Vyne |
Vyne Therapeutics Relative Risk vs. Return Landscape
If you would invest 257.00 in Vyne Therapeutics on December 22, 2024 and sell it today you would lose (85.00) from holding Vyne Therapeutics or give up 33.07% of portfolio value over 90 days. Vyne Therapeutics is currently does not generate positive expected returns and assumes 5.3632% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Vyne, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vyne Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vyne Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vyne Therapeutics, and traders can use it to determine the average amount a Vyne Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0982
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VYNE |
Estimated Market Risk
| 5.36 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vyne Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vyne Therapeutics by adding Vyne Therapeutics to a well-diversified portfolio.
Vyne Therapeutics Fundamentals Growth
Vyne Stock prices reflect investors' perceptions of the future prospects and financial health of Vyne Therapeutics, and Vyne Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vyne Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (52.51) % | ||||
| Current Valuation | (35.26 M) | ||||
| Shares Outstanding | 14.75 M | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 52.22 X | ||||
| Revenue | 501 K | ||||
| Gross Profit | 477 K | ||||
| EBITDA | (43.63 M) | ||||
| Net Income | (39.83 M) | ||||
| Cash And Equivalents | 42.81 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 99 K | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 6.29 X | ||||
| Cash Flow From Operations | (33.97 M) | ||||
| Earnings Per Share | 1.72 X | ||||
| Market Capitalization | 44.25 M | ||||
| Total Asset | 66.91 M | ||||
| Retained Earnings | (731.17 M) | ||||
| Working Capital | 49.62 M | ||||
About Vyne Therapeutics Performance
By analyzing Vyne Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Vyne Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vyne Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vyne Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 914.10 | 1,522 | |
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.76) | (0.80) |
Things to note about Vyne Therapeutics performance evaluation
Checking the ongoing alerts about Vyne Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vyne Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vyne Therapeutics generated a negative expected return over the last 90 days | |
| Vyne Therapeutics has high historical volatility and very poor performance | |
| Vyne Therapeutics may become a speculative penny stock | |
| Vyne Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 501 K. Net Loss for the year was (39.83 M) with profit before overhead, payroll, taxes, and interest of 477 K. | |
| Vyne Therapeutics currently holds about 42.81 M in cash with (33.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: VYNE Therapeutics Releases Quarterly Earnings Results, Beats Estimates By 0.03 EPS |
- Analyzing Vyne Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vyne Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vyne Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vyne Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vyne Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vyne Therapeutics' stock. These opinions can provide insight into Vyne Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |